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Antidepressant discontinuation syndrome –  
a case report  
Navin Kumar Devaraj, Aneesa Abdul Rashid, Khadijah Hasanah Abang Abdullah,  
Abdul Hadi Abdul Manap
Antidepressant discontinuation syndrome (ADDS) is often an under-
recognised cause of multiple unpleasant symptoms upon stopping 
antidepressant. It requires a high index of suspicion to not miss this 
elusive diagnosis. This case will look at a common scenario of a 
nursing home resident forgetting to refill his antidepressant 
prescription which lead to the above syndrome. This will lead to 
discussion on how to treat this syndrome and subsequently allow the 
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INTRODUCTION 
Antidepressant discontinuation syndrome 
usually occur within a few days of stopping the 
causative drug.1 It is usually short-lived and 
mild but in certain severe cases, it can lead to 
many unpleasant symptoms and incorrectly 
diagnosed as other condition, thereby leading 
to more non adherence by the patient.1 
The symptoms vary and can include different 
systems and can be rather vague and general 
such as flu-like illness, headache and lethargy 
making it unique as it is not directly related to 
the treating psychiatric illness. Therefore, the 
condition can be mistaken as other 
neurological conditions, infectious diseases or 
adverse effects of other medications taken by 
the patient.2 
All antidepressant groups including 
monoamine oxidase inhibitors (MAOI), 
selective serotonin reuptake inhibitors (SSRI) 
and tricyclic antidepressant (TCA), have the 
potential to cause this syndrome.1,3 As 
compared to longer acting antidepressant 
such as fluoxetine, shorter acting 
antidepressant such as paroxetine and 
venlafaxine have higher potential to cause 
antidepressant discontinuation syndrome.3 
CASE REPORT 
Mr. K is a 49-years-old Chinese man who 
presented with history of crying spells for the 
past 3 days. He was accompanied by his 
caretaker in the nursing home. He claimed he 
has been crying without any apparent reason 
or control. It was associated with nightmares 
and insomnia. There was also increase in 
salivation, rhinorrhoea, nausea and dizziness. 
There was no blurring of vision or syncope. 
There is no suicidal ideation or aggressive 
behaviour. 
Premorbid, he has hypertension, type 2 
diabetes mellitus and suffered 2 episodes of 
right middle cerebral infarct in 2005 and 2013. 
As a consequent of his recurrent stroke which 
left him dependant on wheelchair, he 
developed depression a year later and was 
started on paroxetine 10mg daily which 
managed to control most of his depressive 
symptoms which included low mood, feeling of 
worthlessness, anxiety and irritability with the 
absence of crying spells. He is on 8 types of 
medications for his hypertension, diabetes, 
stroke and depression. 
Physical examination showed an alert middle-
aged man who was crying in between the 
consultation. He maintained good eye contact 
and had slurred speech. His vital signs were 
stable. He is orientated to time, place and 
person. Neurological examination revealed 
hypersalivation with presence of gag reflex. 
The power over his left upper and lower limbs 
was 3/5 with normal power on the opposite 
limb. 
Mr K is a divorcee with no children and no 
contact with his former wife. He has been in 
the nursing home since his second episode of 
stroke. He has no siblings. His parents are his 
only close relative who kept regular contact 
with him. On further history, patient has not 
been taking his antidepressant for the past 
one week as the medicine has finished and he 
missed his last hospital appointment. He also 
complains of feeling irritated by his friends in 
the nursing home as they keep asking him the 
reason for his persistent crying.  
He was treated as a case of antidepressant 
discontinuation syndrome.  His differential 
diagnosis was relapse of his previous 
depression. As paroxetine was not available in 
the clinic, he was started on another selective 
serotonin reuptake inhibitor (SSRI), sertraline. 
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He was given an appointment in 2 weeks in 
which he reported to be well and cheerful with 
no more crying spells and insomnia. His 
salivation and flu-like symptoms also had 
resolved. He, along with his caretaker were 
advised to not stop his antidepressant without 
prior consultation with the treating physician 
and to be more adherent to his hospital 
appointments. 
DISCUSSION 
Antidepressant Discontinuation Syndrome 
(ADDS) occurs after abrupt discontinuation of 
medications that has been taken for a 
minimum of six weeks. The symptoms last for 
one to two weeks and is rapidly halted by the 
re-initiation of the drug taken. There is limited 
data on the prevalence or burden of this 
condition due to several factors including 
issues with diagnosis, and its transient nature. 
It is said around 20% of patients will develop 
this syndrome if the use is abruptly stopped.1 
There are also classifications according to the 
type of treatment used, for example the SSRI 
discontinuation syndrome which is caused by 
the halt of SSRI usage.4 
As many as 50 symptoms have been reported 
to occur in ADDS.5 SSRI and TCA usually share 
the symptoms shown in Table 1:5 
 
Table 1 Common symptoms related to ADDS.5 SSRI and TCA 
Symptom group Example of specific symptoms Common in SSRI Common in TCA 
Sensory Paraesthesia, numbness, visual 
trails 
Yes No 
Disequilibrium Dizziness, light-headedness, 
vertigo 
Yes No 
General somatic Lethargy, headache, sweating, 
tremor, anorexia 
Yes Yes 
Affective Irritability, anxiety, low mood, 
tearfulness 
Yes Yes 
Gastrointestinal Nausea, diarrhoea, vomiting Yes Yes 




This includes general somatic, gastrointestinal, 
affective and sleep-related symptoms.5  
Sensory and disequilibrium symptoms are 
however more with the use of SSRI.5 
However, reactions to MAOI discontinuation 
seems to be the most severe with worsening 
of even baseline depressive symptoms, 
manifestations of acute confusional state with 
paranoid delusions and hallucinations, and 
anxiety symptoms including hyperacusis and 
depersonalization.5  
In order to rapidly remember these symptoms, 
the mnemonic FINISH is used; Flulike 
symptoms, Insomnia, Nausea, Imbalance, 
Sensory disturbance and Hyperarousal 
(anxiety/agitation), which are the six core 
symptoms. It has been reported to be 
experienced by up to 40% of patients who 
have abruptly stopped their treatment.1,6-7 
118
Malta Medical Journal     Volume 33 Issue 01 2021           
There has been other suggestions to identify 
symptoms and use it for the basis of diagnosis, 
in order to help with management of these 
patients. For example, in 2000, a range of 
symptoms were suggested for the SSRI 
discontinuation syndrome which involves two 
or more of the following symptoms:4 
Dizziness, light-headedness, vertigo or feeling 
faint; shock-like sensations or paraesthesia; 
anxiety; diarrhoea; fatigue; gait instability; 
headache; insomnia; irritability; nausea or 
emesis; tremor; and visual disturbances. 
Also taking into consideration is the symptom 
developing within 1-7 days of stopping or 
reduction of medication after 1 month of use, 
the symptoms cause significant distress and 
not cause by other medical conditions.  
However, to our knowledge these criteria has 
not been formally validated.1,4,6 
Diagnosis is usually established based on 
history of stopping the antidepressant. This 
will usually require a high index of suspicion to 
look out for discontinuation symptoms.1  
Management mainly involve restarting 
treatment and symptomatic management of 
troubling symptoms. As is well said, 
“prevention is better than cure”. Therefore, 
pre-emptive advice and education for both 
treating clinicians and patients before starting 
antidepressant about the possibility of 
discontinuation symptoms on suddenly 
stopping antidepressant should be 
emphasised.1,5 
However, this step alone, still does not solve 
the problem. Hence there has been several 
proposed methods in the literature regarding 
this issue. One of which suggests to slowly 
taper down the dose. The rate would depend 
on the medication, so for example those with a 
shorter half- life such as venlafaxine and 
paroxetine should be tapered down more 
gradually within weeks to months.3,8 
Sometimes switching to a longer half-life 
antidepressant; fluoxetine may be warranted.8 
However, switching antidepressants needs to 
be done with caution.3 
Other methods of management have 
suggested alternative management which may 
include a short course of benzodiazepines for 
symptomatic treatment, antimuscarinic agents 
that may help with gastrointestinal symptoms 
and cholinergic rebound in TCA withdrawals, 
and also antipsychotic treatment with patients 
experiencing withdrawal mania.1,8 
Depression is a common presentation in 
primary care and part of the management is 
stopping the treatment once the patient is 
cured, hence primary care physicians should be 
made aware of ADDS and its management.  
The repercussions of the treating clinician not 
familiar with this condition can lead to heavy 
consequences such as medical and psychiatric 
misdiagnosis, and may lead to patient 
unwilling to use psychotropic medications and 
lead to difficult treatment of such patients.1  
Although the symptoms of ADDS was related 
to the non-compliance of this patient, it has 
taught both the authors and patient a valuable 
lesson on this syndrome. This patient is more 
likely to experience ADDS, when trying to 
taper down his antidepressants. Therefore, 
better preparation can be made should this 
decision be agreed upon later on in his course 
of treatment. 
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